Health Jul 02 FDA approves 2nd Alzheimer’s drug that can modestly slow dementia Kisunla is not a cure and slows worsening memory and cognitive problems by about seven months. By Matthew Perrone, Associated Press
Health Jun 10 FDA advisers back Alzheimer’s drug that can slow disease If the agency agrees with the panel's recommendation, the drug, donanemab, would only be the second Alzheimer’s drug cleared in the U.S. shown to convincingly slow cognitive decline and memory problems due to Alzheimer's. By Matthew Perrone, Associated Press
Health Jul 17 A 2nd experimental Alzheimer’s drug shows promise, but comes with safety risks If U.S. regulators approve, the drug would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding. By Lauran Neergaard, Associated Press
Health Mar 14 Novo Nordisk plans major price cuts for several insulins The Danish drugmaker said Tuesday that pre-filled pens and vials of long- and short-acting insulins will see list price reductions. They include Levemir, Novolin, NovoLog and NovoLog Mix70/30. By Tom Murphy, Associated Press
Mar 05 Analysis: Eli Lilly is capping insulin copays at $35. Here are 5 questions answered By Dana Goldman, Karen Van Nuys, The Conversation Two scholars who have researched insulin pricing explain why Eli Lilly is dramatically cutting the cost of some of its insulin products and how it may improve access to this essential medical treatment. Continue reading
Mar 01 Watch 5:12 Pharmaceutical giant slashes insulin prices after pressure from government and consumers By Geoff Bennett, Courtney Norris More than seven million Americans rely on insulin and prices for the life-saving drug have sky-rocketed. With pressure mounting on pharmaceutical companies to address the cost of diabetes care, Eli Lilly announced it’s cutting prices for its most popular insulin… Continue watching
Mar 01 Eli Lilly to cut insulin prices, as low as $25 a vial for most common drug By Tom Murphy, Associated Press Eli Lilly will cut prices for some older insulins later this year and immediately expand a limit on costs insured patients pay when they fill prescriptions. Continue reading
Nov 09 U.S. allows emergency use of COVID-19 antibody drug By Matthew Perrone, Associated Press The Food and Drug Administration on Monday cleared the experimental drug from Eli Lilly for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. Continue reading
Aug 18 Watch Alzheimer’s Treatment Research Dealt Setback An effort to develop a treatment for Alzheimer's disease was halted after data showed that a new drug was doing more harm than good, leading to more memory loss and putting people at a higher risk for skin cancer. Judy… Continue watching